Rxo Book Value Per Share Growth & History (RXO)
Rxo's book value per share was $9.39 for fiscal 2025.
View full Rxo company overviewRxo annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.39 | -$0.53 | −5.36% |
| 2024 | 2024-12-31 | $9.92 | $4.84 | +95.42% |
| 2023 | 2023-12-31 | $5.08 | $0.03 | +0.65% |
| 2022 | 2022-12-31 | $5.04 | -$4.25 | −45.72% |
| 2021 | 2021-12-31 | $9.29 | $0.02 | +0.19% |
| 2020 | 2020-12-31 | $9.27 | — | — |
Rxo quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.13 | -$0.55 | −5.71% |
| Q1 2026 | 2026-03-31 | $9.15 | -$0.53 | −5.47% |
| Q4 2025 | 2025-12-31 | $9.39 | -$0.53 | −5.36% |
| Q3 2025 | 2025-09-30 | $9.63 | -$0.65 | −6.29% |
| Q2 2025 | 2025-06-30 | $9.68 | $4.76 | +96.72% |
| Q1 2025 | 2025-03-31 | $9.68 | $4.73 | +95.54% |
| Q4 2024 | 2024-12-31 | $9.92 | $4.84 | +95.42% |
| Q3 2024 | 2024-09-30 | $10.27 | $5.23 | +103.75% |
| Q2 2024 | 2024-06-30 | $4.92 | -$0.11 | −2.24% |
| Q1 2024 | 2024-03-31 | $4.95 | -$0.05 | −1.10% |
| Q4 2023 | 2023-12-31 | $5.08 | $0.03 | +0.65% |
| Q3 2023 | 2023-09-30 | $5.04 | -$4.79 | −48.73% |
| Q2 2023 | 2023-06-30 | $5.04 | — | — |
| Q1 2023 | 2023-03-31 | $5.01 | — | — |
| Q4 2022 | 2022-12-31 | $5.04 | — | — |
| Q3 2022 | 2022-09-30 | $9.84 | — | — |
Rxo book value per share trends
Over the last five fiscal years, Rxo's book value per share increased from $9.27 to $9.39, a change of $0.11. The latest reported quarter, Q2 2026, shows $9.13.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rxo source filings ↗